Keith Boundy - Merck & Co Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Susanna K. Tan,Deborah Cebrik, David Plotnik,Maria L. Agostini,Keith Boundy,Christy M. Hebner,Wendy W. Yeh,Phillip S. Pang,Jaynier Moya,Charles Fogarty, Manuchehr Darani,Frederick G. Hayden

CLINICAL INFECTIOUS DISEASESno. 4 (2024): 1054-1061

引用0浏览0WOS引用

A Phase 1 Study in Healthy Volunteers to Investigate the Safety, Tolerability, and Pharmacokinetics of VIR-2482: a Monoclonal Antibody for the Prevention of Severe Influenza A Illness

David Plotnik,Jennifer E. Sager, Madhukar Aryal,Marie C. Fanget,Alessia Peter,Michael A. Schmid,Deborah Cebrik,Erik Mogalian,Keith Boundy,Wendy W. Yeh,Paul Griffin,Maribel Reyes

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY（2024）

引用0浏览0WOS引用

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Frederic Vanhoutte, Wen Liu,Richard T. Wiedmann, Liesbeth Haspeslagh,Xin Cao,Keith Boundy,Antonios Aliprantis, Michelle Davila,Jonathan Hartzel,Jianing Li, Mac McGuire,Katrin Ramsauer,Yvonne Tomberger,Roland Tschismarov,Deborah D. Brown,Weifeng Xu,Jeffrey R. Sachs,Kevin Russell,S. Aubrey Stoch,Eseng Lai

EBIOMEDICINE (2022)

引用0浏览0引用

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

Pratik Bhagunde,Francheska Colon-Gonzalez,Yang Liu,Jin Wu, Shiyao Sherrie Xu,Graigory Garrett,Patricia Jumes,Kenneth Lasseter,Thomas Marbury,Matthew L. Rizk,Mallika Lala,Elizabeth G. Rhee,Joan R. Butterton,Keith Boundy

British journal of clinical pharmacology（2020）

引用7浏览0WOS引用

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

Keith Boundy,Yang Liu,Pratik Bhagunde,Terry E O'Reilly,Francheska Colon-Gonzalez,Evan J Friedman,Mallika Lala,Elizabeth G Rhee,Matthew L Rizk

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT（2020）

引用2浏览0WOS引用

健常人におけるイミペネムおよびシラスタチンと併用したβ-ラクタマーゼ阻害剤,レレバクタムの単回および複数用量の薬物動態,安全性および忍容性【JST・京大機械翻訳】

Goodrick Elizabeth,Luzum Matthew,Calder Nicole,Marcela Nefliu,Jiang Steven,S Schwartz Michael,M. Fèvre Eric,Boundy Keith,Bhagunde Pratik,Francheska Colón‐González,J. Kiley Patricia, Liu Yang,Romani-Aumedes Joan

Antimicrobial Agents and Chemotherapyno. 9 (2018)

引用0浏览0引用

Erratum for Rhee et al., “Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants”

Elizabeth G. Rhee,Matthew L. Rizk,Nicole Calder,Marcela Nefliu,Steven J. Warrington,Michael S. Schwartz,Eric Mangin,Keith Boundy,Pratik Bhagunde,Francheska Colon-Gonzalez,Patricia Jumes, Yang Liu,Joan R. Butterton

Antimicrobial Agents and Chemotherapyno. 12 (2018)

引用0浏览0引用

Erratum for Rhee Et Al., “pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a Β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants”

Antimicrobial Agents and Chemotherapyno. 12 (2018)

引用0浏览0引用

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a Β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Antimicrobial Agents and Chemotherapy（2018）

引用45浏览0WOS引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn